Blood glucose Measure Dapagliflozin monotherapy in 389 treatment-naïve patients in a 12-week study Dapagliflozin as an add-on to metformin in 546 patients inadequately controlled by metformin alone in a 24-week study Dapagliflozin combination therapy in 71 patients inadequately controlled by insulin plus OADs in a 12-week study
  2.5mg 5mg 10mg 20mg 50mg Placebo 2.5 mg 5mg 10mg Placebo 10mg 20mg Placebo
Mean change from baseline in FPG (mg/dl) -16 -19 -21 -24 -31 -6 -17.8 -21.5 -23.5 -6.0 -2.4 -9.6 17.8
Change from baseline in PPG -9382a -8478a -10149a -7053a -10,093a -3182a         -34.3b -41.9b 18.7a
Mean absolute change from baseline in HbA1c (%) -0.71 -0.72 -0.85 -0.55 -0.90 -0.18 -0.67 -0.70 -0.84 -0.30 -0.61 -0.69 0.09
AUC: Area Under the Curve; FPG: Fasting Plasma Glucose; HbA1c: Hemoglobin A1c; OAD: Oral Antidiabetic Drug; PPG: Postprandial Plasma Glucose. aMean change in AUC ((mg/dL)*min), bPlasma glucose levels measured after 120 min during a 75 g oral glucose tolerance test [31].
Table 3: Effect of dapagliflozin on blood glucose parameters.